A single-center, randomized, parallel, positive control and open clinical trial of Yiqi Tongluo Xiezhuo recipe was carried out in 18-75-year-old patients with CKD stage III-IV (syndrome of qi&

Dongzhimen Hospital, Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) meet the diagnostic criteria of CKD III-V in the 2012 KIDIGO guidelines, and effectively control the reversible factors that may lead to the aggravation or progression of the disease, such as infection, electrolyte disturbance, hypertension, hyperglycemia, etc.; (2) meet the diagnostic criteria of TCM syndrome of qi deficiency and blood stasis and damp-heat syndrome; (3) 18-75 years old; (4) voluntary subjects who understand and sign the informed consent form

•(1) secondary chronic renal insufficiency caused by systemic lupus erythematosus; (2) patients who have received or are undergoing dialysis; renal transplant patients (3) with severe primary diseases of the heart, liver, brain, blood and other organs or systems, or with consumptive diseases such as tumors, hyperthyroidism, severe inflammation, etc. (4) those who have participated in clinical trials within 3 months or have used glucocorticoids, immunosuppressive drugs, Tripterygium wilfordii preparations, or are receiving the above treatment; (5) 24-hour urinary protein = 3.0g; serum albumin = 25g / L; (6) pregnant or lactating women: (7) those who are known to be allergic to drug ingredients; (8) the range of GFR fluctuation = 30% in the first 3 months of the group.

发起方

Dongzhimen Hospital, Beijing University of Chinese Medicine